323 related articles for article (PubMed ID: 33620251)
1. Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2021 Apr; 10(6):495-507. PubMed ID: 33620251
[No Abstract] [Full Text] [Related]
2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA; Drudge C; Walsh S; Tiwari S; Brennan R; Boer I; Häring DA; Klotz L; Adlard N; Banhazi J
J Comp Eff Res; 2023 Jul; 12(7):e230016. PubMed ID: 37265062
[No Abstract] [Full Text] [Related]
4. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
5. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
6. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of ofatumumab
Riley N; Drudge C; Nelson M; Haltner A; Barnett M; Broadley S; Butzkueven H; McCombe P; Van der Walt A; Wong EOY; Merschhemke M; Adlard N; Walker R; Samjoo IA
Ther Adv Neurol Disord; 2024; 17():17562864241239453. PubMed ID: 38525490
[TBL] [Abstract][Full Text] [Related]
8. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
10. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
Bhan V; Clift F; Baharnoori M; Thomas K; Patel BP; Blanchette F; Adlard N; Vudumula U; Gudala K; Dutta N; Grima D; Mouallif S; Farhane F
J Comp Eff Res; 2023 Sep; 12(9):e220175. PubMed ID: 37606897
[No Abstract] [Full Text] [Related]
11. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
[TBL] [Abstract][Full Text] [Related]
14. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
15. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
Liu Z; Liao Q; Wen H; Zhang Y
Autoimmun Rev; 2021 Jun; 20(6):102826. PubMed ID: 33878488
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
[TBL] [Abstract][Full Text] [Related]
18. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
19. Drugs for multiple sclerosis.
Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
[No Abstract] [Full Text] [Related]
20. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
